Thrombosis in multiple myeloma

Expert Review of Anticancer Therapy

Volumn 7, Issue 3, 2007, Pages 307-315

  Zangari, Maurizio ^a   Elice, Francesca ^b   Fink, Louis ^c   Tricot, Guido ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b SAN BORTOLO HOSPITAL   (Italy)

^c NEVADA CANCER INSTITUTE   (United States)

Author keywords

Anticoagulation; Myeloma; Survival; Thalidomide; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOGENESIS INHIBITOR; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 7; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC AGENT; DALTEPARIN; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; ETOPOSIDE; IMMUNOGLOBULIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; NADROPARIN; PARAPROTEIN; PREDNISONE; PROTEIN C; STEROID; THALIDOMIDE; VON WILLEBRAND FACTOR; WARFARIN;

ANTICOAGULATION; CATHETER THROMBOSIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG WITHDRAWAL; FIBRINOLYSIS; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PARAPROTEINEMIA; PATIENT SELECTION; REVIEW; TERATOGENICITY; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; BLOOD COAGULATION FACTORS; CYTOKINES; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INCIDENCE; MULTIPLE MYELOMA; MYELOMA PROTEINS; PARAPROTEINEMIAS; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; THALIDOMIDE; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS;

EID: 33947683449     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.3.307     Document Type: Review

References (79)

1. Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N. Engl. J. Med 344(25), 1951-1952 (2001).
2. Tricot G. Multiple myeloma and other plasma cell disorders. In: Hematology. Basic Principles and Practice (4th Edition). Hoffman R (Ed.). Elsevier Churchill Livingston Editions, London, UK Chapter 83, 1501-1535 (2005).
3. Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet 351(9109), 1077-1080 (1998).
4. Prandoni P, Lensing AW, Buller HR et al. Deep-vein thrombosis and incidence of subsequent symptomatic cancer. N. Engl. J. Med. 327(16), 1128-1133 (1992).
5. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med 343(25), 1846-1850 (2000).
6. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest 124(3 Suppl.), S58-S68 (2003).
7. Sallah S, Husain A, Wan J, Vos P, Nguyen NP. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann. Oncol. 15(10), 1490-1494(2004).
8. Srkalovic G, Cameron MG, Rybicki L et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 101(3), 558-566 (2004).
9. Barlogie B, Desikan R, Eddlemon P et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a Phase 2 study of 169 patients. Blood 98(2), 492-494 (2001)
10. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 107(23 Suppl. 1), 117-121 (2003).
11. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA 91(9), 4082-4085 (1994).
12. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin. Pharmacol. Ther. 6, 303-306 (1965).
13. Singhal S, Mehra J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med 341(21), 1565-1571 (1999).
14. Tosi P. Zamagni E, Cellini C et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 87(4), 408-414 (2002).
15. Kumar S, Gertz MA, Dispenzieri A et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin. Proc. 78(1), 34-39 (2003).
16. Cavo M, Zamagni E, Tosi P et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89(7), 826-831 (2004).
17. Zangari M, Anaissie E, Barlogie B et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98(5), 1614-1615 (2001).
18. Bartlett JB, Michael A, Clarke IA et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br. J. Cancer 90(5), 955-961 (2004).
19. Zangari M, Elice F, Tricot G. Immunomodulatory drugs in multiple myeloma. Expert Opin. Investig. Drugs 14(11), 1411-1418 (2005).
20. Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refactory multiple myeloma (MM): results of a North American Phase III study (MM-009). J. Clin. Oncol. 24(S18) (2006) (Abstract 7521).
21. Dimopoulos MA, Spencer A, Attal M et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a Phase 3 study (MM-010). Blood, 106, (2005) (Abstract 6).
22. Donati MB, Falanga A. Pathogenetic mechanism of thrombosis in malignancy. Acta Haematol. 106(1-2), 18-24 (2001).
23. Gouin-Thibault I, Achkar A, Samama MM. The thrombophilic state in cancer patients. Acta Haematol, 106(1-2), 33-42 (2001).
24. Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 4(6), 465-473 (2002).
25. Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink L, Tricot G. The blood coagulation mechanism in multiple myeloma. Semin. Thromb. Hemost. 29(3), 275-282 (2003).
26. Zangari M, Siegel E, Barlogie B et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 100(4), 1168-1171(2002).
27. Kaushal V, Kaushal GP, Melkaveri SN, Mehra P. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J. Thromb. Haemost. 2(2), 327-334 (2004).
28. Zangari M, Barlogie B, Thertulien R et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin. Lymphoma 4(1), 32-35 (2003).
29. Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br. J. Haematol. 134(4), 399-405 (2006).
30. Otterson GA, Monahan BP, Harold N, Steinberg SM, Frame JN, Kaye FJ. Clinical significance of the FV:Q506 mutation in unselected oncology patients. Am. J. Med. 101(4), 406-412 (1996).
31. Santos AB, Llamas P, Roman A et al. Evaluation of thrombophylic states in myeloma patients receiving thalidomide: a reasonable doubt. Br J Haematol. 122(1), 159-160 (2003).
32. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 355(9200), 248-250 (2000).
33. Amrani DL. Regulation of fibrinogen biosynthesis: glucocorticoid and interleukin-6 control. Blood Coagul. Fibrinolysis 1(4-5), 443-446 (1990).
34. Stirling D, Hannant WA, Ludlam CA. Transcriptional activation of the factor VIII gene in liver cell lines by interleukin-6. Thromb. Haemost. 79(1), 74-78 (1998).
35. Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J. Thromb. Haemost. 1(3), 445-449 (2003).
36. Esmon CT. Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis. Baillieres Best Pract. Res. Clin. Haematol. 12(3), 343-359 (1999).
37. Deitcher SR, Erban JK, Limentani SA. Acquired free protein S deficiency associated with multiple myeloma: a case report. Am. J. Hematol. 51(4), 319-323 (1996).
38. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc. Natl Acad. Sci. USA 90(3),1004-1008 (1993).
39. Bertina RM, Koeleman BP, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369(6475), 64-67 (1994).
40. Green D, Maliekel K, Sushko E, Akhtar R, Soff GA. Activated-protein-C resistance in cancer patients. Haemostasis 27(3), 112-118 (1997).
41. Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am. J. Med. 110(2), 91-96 (2001).
42. Zangari M, Saghafifar F, Anaissie E et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul. Fibrinolysis 13(3), 187-192 (2002).
43. Hugo JZ, Jeane DM. Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thromb. J. 4, 11 (2006).
44. Gabriel DA, Smith LA, Folds JD, Davis L, Cancelosi SE. The influence of immunoglobulin (IgG) on the assembly of fibrin gels. J. Lab. Clin. Med 101(4), 545-552 (1983).
45. Carr ME Jr, Dent RM, Carr SL. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. J. Lab. Clin. Med 128(1), 83-88 (1996).
46. Yagci M, Sucak GT, Haznedar R. Fibrinolytic activity in multiple myeloma. Am. J. Hematol 74(4), 231-237 (2003).
47. van Marion AM, Auwerda JJ, Minnema MC et al. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb. Haemost. 94(6), 1341-1343 (2005).
48. Yasin Z, Quick D, Thiagarajan P, Spoor D, Caraveo J, Palascak J. Light-chain paraproteins with lupus anticoagulant activity. Am. J. Hematol. 62(2), 99-102 (1999).
49. Takamiya O, Machida S, Okuda M, Nojima J, Koreeda C, Kubara K. A non-immunological phospholipid-dependent coagulation inhibitor associated with IgGλ-type multiple myeloma. Am. J. Hematol, 75(1), 34-39 (2004).
50. Ward CM, Yen T, Harvie R, Pavlakis N. Elevated levels of factor VIII and von Willebrand factor after thalidomide treatment for malignancy: relationship to thromboembolic events. Hematol, J. 4(Suppl. 1) (2003) (Abstract 265).
51. Corso A, Lorenzi A, Terulla V et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann. Hematol. 83(9), 588-591 (2004).
52. Bertolini F, Mingrone W, Alietti A et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann. Oncol, 12(7), 987-990 (2001).
53. Neben K, Moehler T, Kraemer A et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br. J. Haematol. 115(3), 605-608 (2001).
54. Geerts WH, Pineo GF, Heir JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl.), S338-S400 (2004).
55. Kakkar AK, Levine MN, Kadziola Z et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J. Clin. Oncol. 22(10), 1944-1948 (2004).
56. Cunningham MS, White B, Hollywood D, O'Donnell J. Primary thromboprophylaxis for cancer patients with central venous catheters - a reappraisal of the evidence. Br. J. Cancer 94(2), 189-194 (2006).
57. Perret-Guillaume C, Wahl DG. Low-dose warfarin in atrial fibrillation leads to more thromboembolic events without reducing major bleeding when compared to adjusted-dose - a meta-analysis. Thromb. Haemost. 91(2), 394-402 (2004).
58. Lee AY, Levine MN, Baker RI et al. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med 349(2), 146-153 (2003).
59. Baz R, Li L, Kottke-Marchant K et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin. Proc. 80(12), 1568-1574 (2005).
60. Zangari M, Barlogie B, Anaissie E et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br. J. Haematol, 126(5), 715-721 (2004).
61. Weber D, Rankin K, Gavino M et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol, 21, 16-19 (2003).
62. Minnema MC, Breitkreutz I, Auwerda JJ et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thatidomide and chemotherapy. Leukemia 18(12), 2044-2046 (2004).
63. Hussein MA. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb. Haemost. 95(6), 924-930 (2006).
64. Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106(13), 4050-4053 (2005).
65. Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 108(1), 403 (2006).
66. Baz R, Walker E, Karam M et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann. Oncol. 17(12), 1766-1771 (2006).
67. Zangari M, Barlogie B, Cavallo F et al. Effect on survival of treatment associated venous thromboembolism in newly diagnosed multiple myeloma patients. Blood Coagul. Fibrinolysis (2006) (In Press).
68. Baz R, Hussein MA Does low-dose aspirin have antineoplastic effects in multiple myeloma? Br. J. Haematol, 134(3), 349-350 (2006).
69. Rajkumar SV, Gertz MA, Lacy MQ et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 17(4), 775-779 (2003).
70. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin. Oncol. 24(3), 431-436 (2006).
71. Palumbo A, Rus C, Zeldis JB, Rodeghiero, F, Boccadoro M. Italian Multiple Myeloma Network, Gimema. Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J. Tbromb. Haemost. 4(8), 1842-1845 (2006).
72. Oakervee H, Baugh H, Boots M et al. A study of the safety and efficacy of oral melphalan, prednisolone and thalidomide (MPT) in the treatment of multiple myeloma: a UK Myeloma Forum Pilot Study. Br. J Haematol. 117 (Suppl. 1), 66 (2002).
73. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br. J. Haematol. 121(5), 768-771 (2003).
74. Urbauer E, Kaufmann H, Nosslinger T, Raderer M, Drach J. Thromboembolic events during treatment with thalidomide. Blood 99 (11), 4247-4248 (2002).
75. Moehler TM, Neben K, Benner A et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 98(13), 3846-3848 (2001).
76. Hassoun H, Reich L, Klimek VM et al. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br. J. Haematol. 132(2), 155-161 (2006).
77. Palumbo A, Bertola A, Falco P et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol. J. 5(4), 318-324 (2004).
78. Dimopoulos MA, Zervas K, Kouvatseas G et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann. Oncol. 12(7), 991-995 (2001).
79. Zervas K, Dimopoulos MA, Hatzicharissi E et al. Greek Myeloma Study Group. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and doxamethasone (T-VAD doxil): a Phase II multicenter study. Ann. Oncol. 15(1), 134-138 (2004).